Moclobemide 150mg tablets
What this means
The MHRA has issued a medicines recall or defect notification. Class 1: risk to life, immediate recall. Class 2: may cause mistreatment or harm, recall within 48 hours. Class 3: unlikely to cause harm, recall within 5 days. Class 4 (defect notification): no recall, caution in use. The medicine remains licensed; only the listed batches are affected. Do not stop treatment without speaking to your doctor or pharmacist.
Class 4 defect notification · DMRC - 37693641
| Product | Licence | Active ingredient | GTIN |
|---|---|---|---|
| Moclobemide 150mg tablets | Moclobemide | 05037015030871 |
Batches (expiry): I3602 (30/09/2027), H4610 (31/05/2029)
Background: Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for the batches listed in this notification is missing important updated safety information. Lexon UK Ltd has confirmed that 326 packs of the affected batches are already distributed in the market. The missing information from the PIL is detailed in this notification: 2. What you need to know before you take Moclobemide